Menu
Search
|

Menu

Close
X

Intra-Cellular Therapies Inc ITCI.OQ (NASDAQ Stock Exchange Global Select Market)

19.49 USD
+0.90 (+4.84%)
As of Oct 16
chart
Previous Close 18.59
Open 18.73
Volume 18,647
3m Avg Volume 117,031
Today’s High 19.59
Today’s Low 18.54
52 Week High 25.74
52 Week Low 13.93
Shares Outstanding (mil) 53.10
Market Capitalization (mil) 875.65
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.332
FY17
-2.131
FY16
-2.693
FY15
-2.918
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.69
Price to Sales (TTM)
vs sector
2,803.96
5.82
Price to Book (MRQ)
vs sector
2.11
4.90
Price to Cash Flow (TTM)
vs sector
--
22.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.96
LT Debt to Equity (MRQ)
vs sector
0.00
12.63
Return on Investment (TTM)
vs sector
-26.58
14.32
Return on Equity (TTM)
vs sector
-26.76
16.04

EXECUTIVE LEADERSHIP

Lawrence Hineline
Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary, Since 2014
Salary: $412,000.00
Bonus: $206,000.00
Andrew Satlin
Executive Vice President and Chief Medical Officer, Since 2017
Salary: $68,269.00
Bonus: $100,000.00
Robert Davis
Senior Vice President and Chief Scientific Officer, Since 2015
Salary: $412,000.00
Bonus: $222,500.00
Michael Halstead
Senior Vice President, General Counsel, Secretary, Since 2014
Salary: $455,300.00
Bonus: $227,700.00
Suresh Durgam
Senior Vice President, Late Stage Clinical Development and Medical Affairs, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

430 E 29th St
NEW YORK   NY   10016-8367

Phone: +1212.9233344

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

SPONSORED STORIES